Healthcare

The reason to look now is a full-year result that combined steady core growth with a genuine catalyst — regulatory clearance for its new pathogen-detection platform, CORIS — even as the market reaction was cautious.

The appeal has always been the economics. Pro Medicus sells cloud-based software with minimal incremental cost, so each new contract flows heavily to profit. FY26 illustrated thatLeveragevividly.

For a company of this size, the US opportunity is potentially transformational, and the numbers are beginning to reflect early traction rather than just promise.

For a clinical-stage company with no approved product, theInvestmentcase rests almost entirely on trial progress and readout timing. On that measure, the year has moved faster than many expected.

Paradigm Biopharmaceuticals (ASX:PAR) closed 10% higher on Friday, 4 September 2026, as investors assessed recent developments across a clinical-stage developer of Zilosul for knee osteoarthritis pain. The company is nearing a key checkpoint in the Phase 3 trial of its lead drug candidate for …

Nexsen (ASX:NXN) is expanding its diagnostic research network across Asia-Pacific as it works to move several point-of-care tests towards clinical and commercial use. Hospital collaboration in Hong Kong, research links with universities and non-dilutive funding have broadened the development platform. The next phase will …

Nexsen (ASX:NXN) is expanding its diagnostic research network across Asia-Pacific as it works to move several point-of-care tests towards clinical and commercial use. Hospital collaboration in Hong Kong, research links with universities and non-dilutive funding have broadened the development platform. The next phase will …